Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients

Table 1

Patient baseline characteristics (𝑛=188).

Parameter	Number	%
Age/years, mean (range)	49.89 (18–80)
Gender
Male	167	88.3
Female	21	11.2
Ascites
Yes	51	27.1
No	137	72.9
Tumor size/cm, mean (range)	8.8 (2–18.8)
Number of tumor lesions
≥3	102	54
<3	86	46
Extrahepatic metastasis
Yes	22	11.7
No	166	88.3
Type of PVTT
Type I	90	47.9
Type II	98	52.1
Arteriovenous Fistula
Yes	32	17
No	156	83
Child-Pugh class
A	152	80.9
B	36	19.1
ECOG
0	18	9.6
1	168	89.4
2	2	1.1
Laboratory tests, mean (range)
Alpha fetoprotein	40486 (1–121000)
Hemoglobin (g/L)	130.1 (80–193)
Platelets (10^9/L)	146.8 (25–480)
International normalized ratio	1.5 (0.83–38.3)
Alanine aminotransferase (U/L)	53.7 (5–984)
Aspartate aminotransferase (U/L)	83.8 (15–1242)
Albumin (g/L)	37.8 (24–50.4)
Total bilirubin (𝜇mol/L)	20.1 (6–112)
Creatinine	80.2 (43–193)

BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; AFP: 𝛼-fetoprotein; PVTT: portal vein tumor thrombosis.